Thermo Fisher Scientific Inc (TMO) Given “Buy” Rating at Leerink Swann
Thermo Fisher Scientific Inc (NYSE:TMO)‘s stock had its “buy” rating reiterated by stock analysts at Leerink Swann in a research note issued on Monday. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q4 2017 earnings at $2.65 EPS, FY2017 earnings at $9.34 EPS, Q1 2018 earnings at $2.37 EPS, Q3 2018 earnings at $2.62 EPS, Q4 2018 earnings at $2.86 EPS, FY2018 earnings at $10.44 EPS, Q1 2019 earnings at $2.65 EPS, Q3 2019 earnings at $2.98 EPS and FY2019 earnings at $11.70 EPS.
TMO has been the topic of several other reports. Jefferies Group LLC reissued a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price on the stock in a research report on Thursday, September 7th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reissued an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $205.71.
Thermo Fisher Scientific (TMO) traded up 0.94% during midday trading on Monday, hitting $193.83. 1,542,960 shares of the stock were exchanged. The stock has a market cap of $75.62 billion, a price-to-earnings ratio of 33.77 and a beta of 1.05. The firm has a 50 day moving average of $191.75 and a 200-day moving average of $178.88. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same period last year, the company earned $2.03 earnings per share. The company’s quarterly revenue was up 13.9% on a year-over-year basis. On average, equities analysts expect that Thermo Fisher Scientific will post $9.36 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc (TMO) Given “Buy” Rating at Leerink Swann” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/31/thermo-fisher-scientific-inc-tmo-given-buy-rating-at-leerink-swann.html.
In related news, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the transaction, the director now owns 38,757 shares in the company, valued at $6,702,635.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. Insiders sold 52,738 shares of company stock worth $9,302,112 in the last 90 days. 0.49% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Proficio Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 253 shares during the period. Chicago Partners Investment Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Cribstone Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 8.7% during the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 50 shares during the period. Sharkey Howes & Javer raised its stake in shares of Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $113,000. Hedge funds and other institutional investors own 83.61% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.